Nanobac Life Sciences Announces Agreement With Johnson Space Center to Study Nanobacteria

http://www.nanobaclabs.com/Newsroom/...ews_2004-09-13

NANOBAC LIFE SCIENCES ANNOUNCES SPACE ACT AGREEMENT WITH NASA:
NASA's Johnson Space Center to Study Nanobacteria

TAMPA, Fla. (September 13, 2004) - Nanobac Life Sciences, Inc.
(OTCPK:NNBP) is pleased to announce the signing of a Space Act
Agreement
with NASA's Johnson Space Center (JSC), Houston Texas, to collaborate
on
research on Nanobacteria and its nature and role in pathological
calcification, including the detection and treatment of the pathogen.
Since Astronauts may be more prone to an increased rate of
pathological
calcification while in a zero gravity environment, the collaboration
will bring a new approach to NASA's need to better understand the
effects of long-term space travel on humans. In addition, Nanobac's
work
provides a model for studying mineralized organic matters that could
aid
NASA in the search for extraterrestrial life.

Nanobac co-founder and Director of Science, Neva Ciftcioglu, Ph.D.
will
remain at NASA JSC as Senior Scientist and principal researcher. Under
the agreement, NASA will provide workspace at JSC for Nanobac's
personnel located at JSC. The agreement further provides Nanobac the
opportunity to work together with a multidisciplinary team of NASA
researchers while having access to basic laboratory services for
nanobacteria science, including electron microscopy, molecular biology
and geology-mineralogy research facilities. Projects ranging from
searching for nanobacteria biosignatures in earth fossils and in Mars
meteorites to diagnosing and treating nanobacteria infection are
anticipated. Nanobac will provide JSC with equipment and specialty
supplies for nanobacteria research and apply its pioneering diagnostic
and treatment experience in the field.

"We are pleased to be able to provide our Director of Science to NASA
for these important projects," commented John Stanton, Nanobac's
President and Chief Executive Officer. "We look forward to a very rich
and rewarding research collaboration with NASA. We appreciate the
opportunity to work with some of the country's most talented
scientists."

This announcement shall not be construed to imply that NASA currently
or
in the future endorses or sponsors any NANOBAC product or service.

About Nanobacteria
Nanobacterium sanguineum (nanobacteria) is the smallest
self-replicating
organism ever detected - at 50 to 500 billionths of a meter, 1/1000th
the size of the smallest previously known bacteria. Nanobacteria have
been implicated in a variety of human diseases associated with
pathological calcification.

Nanobacteria were first discovered in 1988 by a Finnish researcher,
and
Nanobac OY co-Founder Olavi Kajander, M.D., Ph.D. Medical
microbiologist
Neva Ciftcioglu, Ph.D. joined his team in 1991 and their corroborated
work with nanobacteria over the past 13 years has put them at the
forefront of research into this medically important pathogen. Their
research established that the blood-borne nanobacteria forms
slow-growing calcified colonies in arteries and organs.

Nanobac has identified two biomarkers of nanobacterial infection.
These
tests are being developed as the NB2 test, which is composed of the
nanobacteria antigen test, and the nanobacteria IgG antibody test. The
Nanobac IgG test is designed to measure the body's immune response to
the nanobacterial infection. The Company is in the final stages of
development of the nanobacteria antigen test.

About Nanobac Lifesciences
Nanobac Life Sciences, Inc. is dedicated to improving people's health
through the detection and eradication of Nanobacterium sanguineum
(nanobacteria). The Company's pioneering research is establishing the
pathogenic role of nanobacteria in calcification, particularly in
coronary artery heart disease and vascular disease. Nanobac has
identified two biomarkers of nanobacterial infection, and expects to
file for FDA approval of its NB2 ELISA assay to detect nanobacterial
antigen and IgG antibody. It is also leveraging its proprietary
knowledge and intellectual property to develop the first FDA approved
therapeutic to detect and treat nanobacterial infection. The Company
currently markets, through its wholly owned subsidiary, Nanobac
Sciences, a patented nanobiotic regimen that it developed.

Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For
more
information, please visit our website at: www.nanobaclifesciences.com.

Investors are cautioned that certain statements contained in this
document as well as some statements in periodic press releases and
some
oral statements of Nanobac Life Sciences, Inc. officials are
"Forward-Looking Statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 (the 'Act). Forward-Looking
statements include statements which are predictive in nature, which
depend upon or refer to future events or conditions, which include
words
such as "believes," "anticipates," "intends," "plans," "expects," and
similar expressions. In addition, any statements concerning future
financial performance (including future revenues, earnings or growth
rates), ongoing business strategies or prospects, and possible future
Nanobac Life Sciences, Inc. actions, which may be provided by
management, are also forward-looking statements as defined by the Act.
Forward-Looking statements involve known and unknown risks,
uncertainties, and other factors which may cause the actual results,
performance or achievements of the Company to materially differ from
any
future results, performance or achievements expressed or implied by
such
forward-looking statements and to vary significantly from reporting
period to reporting period. Although management believes that the
assumptions will, in fact, prove to be correct or that actual future
results will not be different from the expectations expressed in this
report. These statements are not guarantees of future performance and
Nanobac Life Sciences, Inc. has no specific intention to update these
statements.